BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Clinical Pharmacokinetics of Paritaprevir. Clin Pharmacokinet 2017;56:1125-37. [PMID: 28236252 DOI: 10.1007/s40262-017-0520-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Polepally AR, Wang H, Marroum PJ, Minocha M, Hosmane B, Khatri A, Mensing S, Podsadecki TJ, Cohen DE, Awni WM, Menon RM. Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. AAPS J 2017;19:1523-35. [PMID: 28685397 DOI: 10.1208/s12248-017-0115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Badri PS, Shuster DL, Dutta S, Menon RM. Clinical Pharmacokinetics of Ombitasvir. Clin Pharmacokinet 2017;56:1103-13. [PMID: 28229375 DOI: 10.1007/s40262-017-0518-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Alam N, Angeli MG, Greenblatt DJ. Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. J Pharm Pharmacol 2017;69:1794-801. [PMID: 28990653 DOI: 10.1111/jphp.12821] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vevea JD, Chapman ER. Acute disruption of the synaptic vesicle membrane protein synaptotagmin 1 using knockoff in mouse hippocampal neurons. Elife 2020;9:e56469. [PMID: 32515733 DOI: 10.7554/eLife.56469] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Gao W, Webber AL, Maxwell J, Anderson M, Caro L, Chung C, Miltenburg AMM, Popa S, Van Dyck K, Wenning L, Mangin E, Fandozzi C, Railkar R, Shire NJ, Fraser I, Howell B, Talal AH, Stoch SA. Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection. Clin Pharmacol Ther 2020;107:1325-33. [PMID: 31868916 DOI: 10.1002/cpt.1737] [Reference Citation Analysis]
7 Pirzada RH, Haseeb M, Batool M, Kim M, Choi S. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells 2021;10:1052. [PMID: 33946869 DOI: 10.3390/cells10051052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Yuce M, Sarica Z, Ates B, Kurkcuoglu O. Exploring species-specific inhibitors with multiple target sites on S. aureus pyruvate kinase using a computational workflow. J Biomol Struct Dyn 2022;:1-15. [PMID: 35302925 DOI: 10.1080/07391102.2022.2051743] [Reference Citation Analysis]
9 Gopalakrishnan S, Mensing S, Menon RM, Zha J. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies. Clin Pharmacokinet 2018;57:1407-19. [PMID: 29516428 DOI: 10.1007/s40262-018-0640-y] [Reference Citation Analysis]
10 Hupa KL, Deterding K, Port K, Kimmann M, Manns MP, Wedemeyer H, Cornberg M. Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C? J Hepatol 2018;68:851-3. [PMID: 29175536 DOI: 10.1016/j.jhep.2017.10.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Kwarteng A, Asiedu E, Sylverken A, Larbi A, Mubarik Y, Apprey C. In silico drug repurposing for filarial infection predicts nilotinib and paritaprevir as potential inhibitors of the Wolbachia 5'-aminolevulinic acid synthase. Sci Rep 2021;11:8455. [PMID: 33875732 DOI: 10.1038/s41598-021-87976-4] [Reference Citation Analysis]
12 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of Dasabuvir. Clin Pharmacokinet 2017;56:1115-24. [PMID: 28258380 DOI: 10.1007/s40262-017-0519-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lawitz E, Bidair M, Marbury T, Jones CT, Barve A, Magnusson B, Barkan DT, Bodendorf U, Bracken K, Canino E, Chen D, Dabovic K, Heimbach T, Ison M, Jones CL, Kovacs SJ, Lakshman JP, Li B, Raman P, Steiner-Swiat R, Thohan S, Wong KA, Zhong W, Colvin RA. The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial. Clin Ther 2018;40:1567-1581.e4. [PMID: 30185394 DOI: 10.1016/j.clinthera.2018.07.019] [Reference Citation Analysis]
15 Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis 2018;217:474-82. [PMID: 29228392 DOI: 10.1093/infdis/jix495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]